Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417062 · ClinicalTrials.gov registry record · Phase 2
Olaparib With Ceralasertib in Recurrent Osteosarcoma
A Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 4
- Study locations
NCT04417062 is a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 63 participants, below the 300-participant average among 46 other Osteosarcoma trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04417062, a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Ceralasertib
Study Locations (4)
California
- UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology - San Francisco
Massachusetts
- Dana Farber Cancer Institite - Boston
New York
- Memorial Sloan Kettering - New York
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417062
The ClinicalTrials.gov registry entry for NCT04417062 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 46 other Osteosarcoma trials with a reported enrollment target (79% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT04417062 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04417062 about?
NCT04417062 is a clinical study titled "Olaparib With Ceralasertib in Recurrent Osteosarcoma". This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib
What is the current status of trial NCT04417062?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2020-11-24. Estimated completion is 2026-06-01.
What conditions does trial NCT04417062 study?
This clinical trial studies the following conditions: Osteosarcoma, Osteosarcoma Recurrent.
What interventions are being tested in trial NCT04417062?
The interventions under investigation include: Olaparib (DRUG), Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT04417062?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04417062 being conducted?
This trial has 4 study locations across California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.